• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Hiroaki Wakimoto, MD, PhD


  • Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, Cahill DP, Nahed BV, Curry WT, Martuza RL, Louis DN, Rozenblatt-Rosen O, Suvà ML, Regev A, Bernstein BE.Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.Science. 2014 Jun 20(6190):1396-401.
  • Wakimoto H, Tanaka S, Curry WT, Loebel F, Zhao D, Tateishi K, Chen J, Klofas LK, Lelic N, Kim JC, Dias-Santagata D, Ellisen LW, Borger DR, Fendt SM, Vander Heiden MG, Batchelor TT, Iafrate AJ, Cahill DP, Chi AS.Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.Clin Cancer Res. 2014 Jun 1(11):2898-909.
  • Duebgen M, Martinez-Quintanilla J, Tamura K, Hingtgen S, Redjal N, Wakimoto H, Shah K.Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy.Journal of the National Cancer Institute. 2014 Jun;106(6).
  • Suvà ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, Rabkin SD, Riggi N, Chi AS, Cahill DP, Nahed BV, Curry WT, Martuza RL, Rivera MN, Rossetti N, Kasif S, Beik S, Kadri S, Tirosh I, Wortman I, Shalek AK, Rozenblatt-Rosen O, Regev A, Louis DN, Bernstein BE.Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells.Cell. 2014 Apr 24;157(3):580-94.
  • Ning J, Wakimoto H, Rabkin SD.Immunovirotherapy for glioblastoma.Cell Cycle. 2014 Jan 15;13(2):175-6.
  • Tamura K, Aoyagi M, Ando N, Ogishima T, Wakimoto H, Yamamoto M, Ohno K.Expansion of CD133-positive glioma cells in recurrent de novo glioblastomas after radiotherapy and chemotherapy.J Neurosurg. 2013 Nov;119(5):1145-55.
  • Cheema TA, Wakimoto H, Fecci PE, Ning J, Kuroda T, Jeyaretna DS, Martuza RL, Rabkin SD.Multifaceted oncolytic virus therapy for glioblastoma in an immunocompetent cancer stem cell model.Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):12006-11.
  • Zhang W, Fulci G, Wakimoto H, Cheema TA, Buhrman JS, Jeyaretna DS, Stemmer Rachamimov AO, Rabkin SD, Martuza RL.Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models.Neoplasia. 2013 Jun;15(6):591-9.
  • Rheinbay E, Suvà ML, Gillespie SM, Wakimoto H, Patel AP, Shahid M, Oksuz O, Rabkin SD, Martuza RL, Rivera MN, Louis DN, Kasif S, Chi AS, Bernstein BE.An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma.Cell Rep. 2013 May 30;3(5):1567-79.
  • Tamura K, Wakimoto H, Agarwal AS, Rabkin SD, Bhere D, Martuza RL, Kuroda T, Kasmieh R, Shah K.Multimechanistic tumor targeted oncolytic virus overcomes resistance in brain tumors.Mol Ther. 2013 Jan;21(1):68-77.
  • Sgubin D, Wakimoto H, Kanai R, Rabkin SD, Martuza RL.Oncolytic herpes simplex virus counteracts the hypoxia-induced modulation of glioblastoma stem-like cells.Stem Cells Transl Med. 2012 Apr;1(4):322-32.
  • van de Water JA, Bagci-Onder T, Agarwal AS, Wakimoto H, Roovers RC, Zhu Y, Kasmieh R, Bhere D, Van Bergen En Henegouwen PM, Shah K.Therapeutic stem cells expressing variants of EGFR-specific nanobodies have antitumor effects.Proc Natl Acad Sci U S A. 2012 Oct 9;109(41):16642-7.
  • Barnard Z, Wakimoto H, Zaupa C, Patel AP, Klehm J, Martuza RL, Rabkin SD, Curry WT.Expression of FMS-like tyrosine kinase 3 ligand by oncolytic herpes simplex virus type I prolongs survival in mice bearing established syngeneic intracranial malignant glioma.Neurosurgery. 2012 Sep;71(3):741-8; discussion 748.
  • Bagci-Onder T, Wakimoto H, Anderegg M, Cameron C, Shah K.A dual PI3K/mTOR inhibitor, PI-103, cooperates with stem cell-delivered TRAIL in experimental glioma models.Cancer Res. 2011 Jan 1;71(1):154-63.
  • Chen PC, Wakimoto H, Conner D, Araki T, Yuan T, Roberts A, Seidman CE, Bronson R, Neel BG, Seidman JG, Kucherlapati R.Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.J Clin Invest. 2010 Dec 1;120(12):4353-65.
  • Mikheeva SA, Mikheev AM, Petit A, Beyer R, Oxford RG, Khorasani L, Maxwell JP, Glackin CA, Wakimoto H, González-Herrero I, Sánchez-García I, Silber JR, Horner PJ, Rostomily RC.TWIST1 promotes invasion through mesenchymal change in human glioblastoma.Mol Cancer. 2010;9:194.
  • Tamura K, Aoyagi M, Wakimoto H, Ando N, Nariai T, Yamamoto M, Ohno K.Accumulation of CD133-positive glioma cells after high-dose irradiation by Gamma Knife surgery plus external beam radiation.J Neurosurg. 2010 Aug;113(2):310-8.
  • Passer BJ, Cheema T, Zhou B, Wakimoto H, Zaupa C, Razmjoo M, Sarte J, Wu S, Wu CL, Noah JW, Li Q, Buolamwini JK, Yen Y, Rabkin SD, Martuza RL.Identification of the ENT1 antagonists dipyridamole and dilazep as amplifiers of oncolytic herpes simplex virus-1 replication.Cancer Res. 2010 May 15;70(10):3890-5.
  • Kanai R, Wakimoto H, Cheema T, Rabkin SD.Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer?.Future Oncol. 2010 Apr;6(4):619-34. Review.
  • Maguire CA, Gianni D, Meijer DH, Shaket LA, Wakimoto H, Rabkin SD, Gao G, Sena-Esteves M.Directed evolution of adeno-associated virus for glioma cell transduction.J. Neurooncol. 2010 Feb;96(3):337-47.
  • Wakimoto H,Kesari S,Farrell CJ,Curry WT Jr,Zaupa C,Aghi M,Kuroda T,Stemmer-Rachamimov A,Shah K,Liu TC,Jeyaretna DS,Debasitis J,Pruszak J,Martuza RL,Rabkin SD.Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors.Cancer Res. 2009 Apr 15;69(8):3472-81.
  • Sasportas LS,Kasmieh R,Wakimoto H,Hingtgen S,van de Water JA,Mohapatra G,Figueiredo JL,Martuza RL,Weissleder R,Shah K.Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4822-7.